Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc. - Common Shares (NQ:THTX)

2.630 +0.040 (+1.54%)
Streaming Delayed Price Updated: 3:03 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Theratechnologies Inc. - Common Shares

< Previous 1 2 3 4 Next >
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Provides Update on Sale Process
From Theratechnologies
Via GlobeNewswire
Soleus Capital Issues Letter to The Board of Theratechnologies
From Soleus Capital Management, L.P.
Via Business Wire
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
From Theratechnologies
Via GlobeNewswire
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Resumes Distribution of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Theratechnologies Provides Update on EGRIFTA SV® Supply
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Resumed Production of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at Upcoming Investor Conferences in September
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.